Company Active LTD

Company profile

Nanoregmed Ltd

NanoRegMed - Advanced Nanomaterials

NanoRegMed produces and brings to market innovative new materials and components for materials for a wide variety of applications.

CRN
09096454
Founded
2014
Age
12

Overview

Legal name
NANOREGMED LTD
Region
London
Registered address
LONDON BIOSCIENCE INNOVATION CENTRE
2 ROYAL COLLEGE STREET
LONDON
ENGLAND
NW1 0NH
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

Nanoregmed Ltd
No active corporate controller recorded.

Company events

Reference milestones and recent Companies House filing stream events.

9 events
31 Mar
2027

Accounts due

Accounts Due

Next accounts due date

10 Nov
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

27 Oct
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

30 Jun
2025

Accounts filed

Accounts

Last accounts made up date

27 Oct
2024

Confirmation Statement With Updates

Confirmation-statement

CS01 | Transaction MzQ0MTA0NjI4NWFkaXF6a2N4

Published 27 Oct 2024 10:09

28 Aug
2024

Gazette Filings Brought Up To Date

Gazette

DISS40 | Transaction MzQzMzEzNjEyM2FkaXF6a2N4 | Paper/PDF filed

Published 29 Aug 2024 07:00

27 Aug
2024

Gazette Notice Compulsory

Gazette

GAZ1 | Transaction MzQzMjg3MDk5N2FkaXF6a2N4 | Paper/PDF filed

Published 21 Aug 2024 02:28

22 Aug
2024

Confirmation Statement With No Updates

Confirmation-statement

CS01 | Transaction MzQzMzEzNjA2MGFkaXF6a2N4

Published 22 Aug 2024 20:02

23 Jun
2014

Incorporated

Inception

Company registered at Companies House

Public funding

5 awards
First funded
2017
Funded years
2017, 2019, 2021, 2023
Age at first award
3 years

Projects

2023 Collaborative R&D Lead participant

Development of biofunctionalised graphene nerve conduits (NerveGraft) for nerve regeneration

1 Nov 2023 to 31 Oct 2025

Awarded
£126,783
Total cost £181,117

When a nerve is injured due to trauma or tumour resection, it would typically be cut off into two pieces, leaving an empty gap between them. Subsequently, this gap would cause permanent loss of nerve function (i.e. lack of sensation and movement). In 2020, 9,520 nerve injuries were reported in the UK for just upper limbs alone. Current treatments involve ...

2023 Collaborative R&D Lead participant

Development of a novel surgical implant to treat pelvic organ prolapse using advanced materials

1 Jul 2023 to 30 Jun 2024

Awarded
£49,276
Total cost £49,276

Pelvic organ prolapse (POP), a common condition, is the bulging of internal organs down the vaginal canal secondary to weaknesses in the pelvic floor, exacerbated by age and childbirth. A mesh made of polypropylene material was previously used for the surgical management of POP. It has since been banned due to rising concerns that, in the pelvis, the mate...

2021 Collaborative R&D Lead participant

A new pelvic membrane from graphene and stem cells technology

1 Dec 2021 to 30 Nov 2022

Awarded
£13,619
Total cost £13,619

no public description

2019 Collaborative R&D Lead participant

Functionalisation of Graphene Oxide

1 Jan 2019 to 31 Mar 2019

Awarded
£24,822
Total cost £24,822

"We have invented a new advanced material of copolymers to meet the market requirement for the potential application including the development of fouling resistance materials. The materials we have developed include functionalised graphene oxide (FGO). Graphene is currently one of the most exciting advanced materials. It is a disruptive technology, which ...

2017 Feasibility Studies

Development of Graphene Based Anti-Biofouling Coating

1 Sep 2017 to 30 Nov 2018

Awarded
£66,002
Total cost £106,266

Aquaculture is increasing in importance, with over 60% of seafood products expected to come from farms by 2030 (UNFAO). It is a vital industry for global food security and estimated to be worth over $85 billion annually. Biofouling of nets and other submerged infrastructure represents a major challenge for the industry with estimates that dealing with it ...

Product types

Collaborative R&D Feasibility Studies